When biotech start-ups go to present, the common belief is that the technology, biologic, assay, or molecule will be the catalyst for awarding funding. No, it won’t. The fact that you have something that might work and be beneficial to some subset of people worldwide who suffer from a specific condition is how you got in the room. Whether you leave the room with funding is based entirely on what you focus on for the
The concept of perfection in science is prolific. You want your research to suggest that your drug, therapy, etc. will work 100% of the time. That is impossible, but the goal is to get it as close as possible to every time on every patient with the fewest side effects. Most scientists in startups began as highly successful students who experienced some success at larger biotech companies or post-doc labs and then ventured out on
I have helped many teams become more effective at presenting as a team. Because humans are SO different and have SO many variables, it can be quite challenging to coach a team. Most teams preparing on their focus on: who will say what during which slides the order of presenters making the time fair/equal, etc. Often teams are presenting because the stakes are high, and the consequences are critical. And, of course, money is frequently
Team presentations are difficult. They are even more so when there is $10 to $50 million in funding on the line. The presentation sets the tone for the next year or years of your business. So, getting it wrong, messing up, or not presenting as a cohesive unit is not an option. The pressure is high, and the stress over getting it wrong is higher. When we coach teams, who are looking for that essential
One of the statements most often spoken by anyone faced with a big investor presentation is “I need to practice.” For life science start-up CEOs and leadership teams, this is in many cases, a topic of conversation. “I need to practice.” “We need to practice.” “We need to schedule practice.” “This presentation is critical because it influences our funding.” It is common to think practice is easy, but it is not. It is not easy
Welcome to our three-part series that gives biotech CEOs and executive decision-makers the tools to advise, influence, and persuade listeners. After working with numerous Life Science and Biotech clients, we’ve observed that many biotech executives are ill-prepared for delivering their companies essential messagesduring a formal presentation. This blog post, based on our extensive research, explains that there are only three ways to persuade someone of something. If you missed Part 1 or Part 2, be sure to catch
434 Old Connecticut Path Suite 2B | Framingham (Boston), MA 01701 USA
Phone: +1 (617) 739-3330 | Email: [email protected]